Patented: see www.takeda.com/en-us/patents Revised: 10/2025 PRINCIPAL DISPLAY PANEL - Kit Carton - 250 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4622-01 Single-dose only For Intravenous Administration After Reconstitution Only Lyophilized powder for reconstitution ADYNOVATE and diluent preassembled in BAXJECT III system Rx Only Actual potency Takeda PRINCIPAL DISPLAY PANEL - Barrel Label - 250 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Directions for use: see package insert Rx Only IU: LOT: EXP: Takeda 6521221 PRINCIPAL DISPLAY PANEL - Blister Label - 250 IU ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] NDC 0944-4622-02 Single-dose only 6521479 For Intravenous Administration Only ADYNOVATE and diluent preassembled in BAXJECT III system Do not open until time of use Do not use if packaging is opened or damaged Discard unused portion
Don in gastrointestinal diseases with focusing effects on H+/K+-ATPase, calcium channels inhibition and PDE mediated signaling: toxicological evaluation on vital organs
[1] Cell Line:Senescent Leydig cells Concentration:25 mM Incubation Time:3 days Result:The apoptosis rate increased from 10% to 27%
Always consult with a medical practitioner prior to use of this or any dietary supplement
It performs less well when the main issue is severe structural degeneration, uncontrolled overuse, poor sleep, inadequate protein intake, or a problem that requires procedural or surgical care
